BRCA1 and cancer: Since then, ipilimumab + nivolumab has been evaluated in additional cancer types and has received FDA approval for patients with advanced renal cell carcinoma and non-small cell lung cancer [1] while preclinical studies continue to determine the efficacy of this combination in other cancers such as BRCA1-mutated breast cancer [40].